文献速递免疫规划慢病防控与筛查

高剂量与标准剂量三价流感疫苗在类风湿关节炎患者及健康对照中的随机试验

High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.
PubMed 文献 · Vaccine · 2020-04-12

本研究为随机双盲II期试验,纳入接受稳定TNF抑制剂治疗的类风湿关节炎(RA)成人及年龄性别匹配的健康对照,比较高剂量(HD,60 mcg×3株)与标准剂量(SD,15 mcg×3株)流感疫苗的安全性及免疫原性。结果显示RA患者接种HD后第21天血清转化比例高于SD但无统计学显著性,H1N1株GMT抗体反应显著更高,RA与对照间无差异,无安全性担忧。

要点

  • RA患者接受HD疫苗后第21天H1N1株GMT抗体反应显著高于SD。
  • HD与SD在RA患者中均未发现安全性问题,RA症状问卷评分无差异。
  • TNF抑制剂治疗未明显影响SD或HD疫苗的免疫原性。

核心结论

  • 在接受稳定TNF抑制剂治疗的RA患者中,HD疫苗较SD疫苗诱导更高的第21天GMT抗体反应,尤其对H1N1株显著,但血清转化率差异无统计学意义。
  • TNF抑制剂治疗未明显影响SD或HD疫苗的免疫原性,HD与SD均未发现安全性问题。

研究设计与样本

  • 随机、双盲、II期研究,纳入接受TNF抑制剂治疗的RA成人及性别年龄匹配的健康对照。
  • 参与者随机肌内接种HD(Sanofi Pasteur Fluzone High Dose,60 mcg×3株)或SD(Sanofi Pasteur Fluzone,15 mcg×3株)疫苗。

主要发现

  • RA患者接种HD后第21天血清转化比例高于SD,但差异无统计学意义。
  • RA患者接种HD后第21天所有毒株GMT抗体反应均高于SD,其中H1N1株差异显著。
  • RA患者与对照受试者的血清转化率和GMT值无差异。
  • RA患者接种HD或SD后均无安全性担忧,RA症状问卷(RAPID 3)评分在SD与HD组间无差异。

关键数值与推荐

  • HD疫苗为Sanofi Pasteur Fluzone High Dose,每株60 mcg,共3株。
  • SD疫苗为Sanofi Pasteur Fluzone,每株15 mcg,共3株。
  • 免疫原性评估采用血凝抑制(HAI)试验,于接种后第7、21和180天检测。

临床怎么用

  • 对于接受TNF抑制剂治疗的RA患者,HD流感疫苗可能提供更高的抗体反应,尤其对H1N1株,且安全性良好。
  • 鉴于免疫 compromised 人群流感相关发病和死亡风险增加,HD疫苗产生的更高GMT值可能有益。

局限性

  • 血清转化率差异无统计学意义,且HD与SD间的差异较小,需要更大规模的研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Subjects with rheumatoid arthritis (RA) receiving tumor necrosis factor-inhibiting (TNFi) therapies are at risk for severe influenza, and may respond less well to influenza vaccine. We examined the safety and immunogenicity of high dose influenza vaccine (HD) compared to standard dose vaccine (SD) in participants with RA receiving stable TNFi. METHODS: A randomized, double-blinded, Phase II study was conducted in adults with RA receiving TNFi, and healthy, gender and age-matched control subjects. Participants were immunized with HD (Sanofi Pasteur Fluzone High Dose [60 mcg × 3 strains]) or SD (Sanofi Pasteur Fluzone® [15 mcg × 3 strains]) intramuscularly (IM). A self-administered memory aid recorded temperature and systemic and local adverse events (AEs) for 8 days, and safety was evaluated and serum obtained to measure HAI activity on days 7, 21 and 180 days following vaccination. RESULTS: A greater proportion of RA subjects who received HD seroconverted at day 21 compared to SD, although this was not statistically significant. GMT antibody responses in RA subjects who received HD compared to SD were greater for all strains on day 21, and this was significant for H1N1. Seroconversion rates and GMT values were not different between RA subjects and control subjects. There were no safety concerns for HD or SD in RA subjects, and RA-related symptoms did not differ between SD and HD recipients by a RA-symptom questionnaire (RAPID 3). CONCLUSIONS: TNF-inhibitor therapy in people with RA did not appear to influence the immunogenicity of either SD or HD. Influenza seroconversion and GMT values were higher among RA subjects receiving HD compared to SD; however, differences were small and a larger study is needed to validate these findings. Given the apparent risk of increased influenza-related morbidity and mortality among immune compromised subjects, the higher GMT values generated by HD may be beneficial.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Stapleton JT, Wagner N, Tuetken R, et al. High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial. Vaccine. 2020. PMID: 32295718. doi:10.1016/j.vaccine.2020.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。